SLC16A3 and breast cancer: Furthermore, it has been reported that shorter survival of patients in all types of breast cancer, especially in those with the triple-negative phenotype, is associated with high expression of HIF-1α [60], CA9 [61], and BSG [62]; LDHA in lung adenocarcinoma [39]; SLC16A3 in bladder cancer [42]; and SLC2A1 in colorectal cancer [38].